Scroll

icatibant 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
bradykinin receptors antagonists	4186	130308-48-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: icatibant accord WIN-65365 WIN 65365 icatibant firazyr icatibant acetate	a potent bradykinin (B2) receptor antagonist; WIN 65365 is an L-Tic(7) stereoisomer Molecular weight: 1304.54 Formula: C59H89N19O13S CLOGP: -3.47 LIPINSKI: 3 HAC: 32 HDO: 18 TPSA: 516.22 ALOGS: -4.56 ROTB: 30

Molecule

Description

Molfile Inchi Smiles

Synonyms:

icatibant accord
WIN-65365
WIN 65365
icatibant
firazyr
icatibant acetate

a potent bradykinin (B2) receptor antagonist; WIN 65365 is an L-Tic(7) stereoisomer

Molecular weight: 1304.54
Formula: C59H89N19O13S
CLOGP: -3.47
LIPINSKI: 3
HAC: 32
HDO: 18
TPSA: 516.22
ALOGS: -4.56
ROTB: 30

Drug dosage:

Dose	Unit	Route
30	mg	P

ADMET properties:

None

Approvals:

Show entries

Search:

Date	Agency	Company
Aug. 25, 2011	FDA	SHIRE ORPHAN THERAP
July 11, 2008	EMA	Shire Pharmaceuticals Ireland Limited
Sept. 21, 2018	PMDA	Shire Japan KK

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hereditary angioedema	2448.29	25.59	448	5643	7114	63475817
Laryngeal oedema	217.83	25.59	59	6032	5659	63477272
Inappropriate schedule of product administration	214.95	25.59	130	5961	103835	63379096
Pharyngeal oedema	213.85	25.59	71	6020	13650	63469281
Prescribed overdose	166.65	25.59	76	6015	34077	63448854
Pharyngeal swelling	140.44	25.59	43	6048	6361	63476570
Product dose omission issue	130.54	25.59	135	5956	234178	63248753
Injection site pain	129.88	25.59	104	5987	129696	63353235
Product availability issue	126.91	25.59	36	6055	4085	63478846
No adverse event	123.77	25.59	66	6025	41339	63441592

Showing 1 to 10 of 33 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hereditary angioedema	767.60	40.48	110	1205	937	34954679
Inappropriate schedule of product administration	67.90	40.48	37	1278	62259	34893357
Product availability issue	65.46	40.48	15	1300	1872	34953744
Injection site pain	50.44	40.48	26	1289	38979	34916637
Prescribed overdose	43.50	40.48	16	1299	10631	34944985
Angioedema	42.87	40.48	23	1292	37351	34918265
Weight increased	42.63	40.48	32	1283	93001	34862615
Product dose omission issue	41.63	40.48	35	1280	119676	34835940

Showing 1 to 8 of 8 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hereditary angioedema	2148.63	27.59	360	4890	4975	79734163
Pharyngeal oedema	195.12	27.59	63	5187	16209	79722929
Inappropriate schedule of product administration	190.49	27.59	115	5135	133513	79605625
Laryngeal oedema	164.08	27.59	47	5203	8082	79731056
Product availability issue	161.87	27.59	40	5210	3907	79735231
Product dose omission issue	149.17	27.59	126	5124	247411	79491727
Injection site pain	143.04	27.59	95	5155	129743	79609395
Prescribed overdose	111.73	27.59	53	5197	37830	79701308
No adverse event	103.49	27.59	50	5200	37142	79701996
COVID-19	80.15	27.59	73	5177	157601	79581537

Showing 1 to 10 of 25 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	B06AC02	BLOOD AND BLOOD FORMING ORGANS OTHER HEMATOLOGICAL AGENTS OTHER HEMATOLOGICAL AGENTS Drugs used in hereditary angioedema
CHEBI has role	CHEBI:35530	beta-adrenergic blockers
CHEBI has role	CHEBI:63175	peptidomimetics
CHEBI has role	CHEBI:68557	bradykinin receptor antagonists
FDA EPC	N0000182965	Bradykinin B2 Receptor Antagonist
FDA MoA	N0000182964	Bradykinin B2 Receptor Antagonists
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal

Showing 1 to 10 of 18 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hereditary angioneurotic edema	indication	82966003	DOID:14735

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.3	acidic
pKa2	13.85	acidic
pKa3	12.18	Basic
pKa4	10.88	Basic
pKa5	10.16	Basic
pKa6	7.56	Basic

Showing 1 to 6 of 6 entries

Previous1Next

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
B2 bradykinin receptor	GPCR	P30411	BKRB2_HUMAN	ANTAGONIST	Ki	10.22	CHEMBL	CHEMBL
B1 bradykinin receptor	GPCR	P46663	BKRB1_HUMAN	ANTAGONIST	Ki	7	IUPHAR
B2 bradykinin receptor	GPCR		BKRB2_MOUSE	ANTAGONIST	Ki	9.60	IUPHAR
B2 bradykinin receptor	GPCR		BKRB2_RAT		Ki	10.11	CHEMBL
B2 bradykinin receptor	GPCR		BKRB2_CAVPO		Ki	9.96	CHEMBL
B1 bradykinin receptor	GPCR		BKRB1_RAT	ANTAGONIST	Ki	6.40	IUPHAR

Showing 1 to 6 of 6 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
012894	NDDF
012895	NDDF
1148138	RXNORM
138614-30-9	SECONDARY_CAS_RN
160761	MMSL
320534	MMSL
4031108	VUID
4031108	VANDF
667	IUPHAR_LIGAND_ID
6918173	PUBCHEM_CID

Showing 1 to 10 of 24 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Firazyr	HUMAN PRESCRIPTION DRUG LABEL	1	54092-702	INJECTION, SOLUTION	30 mg	SUBCUTANEOUS	NDA	34 sections
Firazyr	HUMAN PRESCRIPTION DRUG LABEL	1	54092-702	INJECTION, SOLUTION	30 mg	SUBCUTANEOUS	NDA	34 sections
Firazyr	HUMAN PRESCRIPTION DRUG LABEL	1	54092-702	INJECTION, SOLUTION	30 mg	SUBCUTANEOUS	NDA	34 sections
Icatibant	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3066	INJECTION, SOLUTION	10 mg	SUBCUTANEOUS	ANDA	27 sections
Icatibant	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3066	INJECTION, SOLUTION	10 mg	SUBCUTANEOUS	ANDA	27 sections
Icatibant	HUMAN PRESCRIPTION DRUG LABEL	1	24201-207	INJECTION, SOLUTION	30 mg	SUBCUTANEOUS	ANDA	29 sections
Icatibant	HUMAN PRESCRIPTION DRUG LABEL	1	24201-207	INJECTION, SOLUTION	30 mg	SUBCUTANEOUS	ANDA	29 sections
Icatibant	HUMAN PRESCRIPTION DRUG LABEL	1	24201-207	INJECTION, SOLUTION	30 mg	SUBCUTANEOUS	ANDA	29 sections
Icatibant	HUMAN PRESCRIPTION DRUG LABEL	1	24201-207	INJECTION, SOLUTION	30 mg	SUBCUTANEOUS	ANDA	29 sections
Icatibant	HUMAN PRESCRIPTION DRUG LABEL	1	54092-135	INJECTION, SOLUTION	30 mg	SUBCUTANEOUS	NDA authorized generic	34 sections

Showing 1 to 10 of 22 entries

Previous1 2 3Next